VSTM - Verastem, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.08
+0.01 (+0.12%)
As of 1:59PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.07
Open7.99
Bid8.05 x 800
Ask8.06 x 1100
Day's Range7.71 - 8.16
52 Week Range2.77 - 9.07
Volume997,412
Avg. Volume2,560,338
Market Cap593.02M
Beta3.45
PE Ratio (TTM)N/A
EPS (TTM)-1.81
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.63
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    Upcoming Catalysts Could Send This Unknown Stock Up 300% or More

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • ACCESSWIRE13 days ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • Business Wire14 days ago

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem, Inc. (VSTM), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced the grant of stock options to nine new employees to purchase an aggregate of 201,500 shares of Verastem Oncology’s common stock. The options were granted as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $6.95 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on July 2, 2018.

  • Business Wire17 days ago

    Verastem Oncology to Participate in the Oppenheimer Boston Oncology Insight Summit

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will participate in the Oppenheimer Boston Oncology Insight Summit on July 10-11, 2018, in Boston, Massachusetts. Members of Verastem Oncology’s executive team will participate in the event. Verastem, Inc. (VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients.

  • Business Wire24 days ago

    Verastem Oncology to Join Russell 3000® Index

    Verastem, Inc. (VSTM), the Company or Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective upon the US market open on Monday, June 25, 2018. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • ACCESSWIRE27 days ago

    Biotech's Making Great Progress

    HENDERSON, NV / ACCESSWIRE / June 22, 2018 / This is set to be the fifth consecutive quarter in which at least ten biotech companies have made it to market on an U.S. exchanges and have raised at least ...

  • ACCESSWIRE29 days ago

    Verastem Upcoming FDA Review, Big Steps Forward in the Oncology Space

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Verastem, Inc. (VSTM), a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The company recently announced the acceptance of its duvelisib New Drug Application by the U.S. Food and Drug Administration, with a Priority Review date later this year. The company recently made one oral and three poster presentations at the 23rd Congress of the European Hematology Association.

  • Analysts’ Recommendations for Verastem
    Market Realistlast month

    Analysts’ Recommendations for Verastem

    This month, Verastem (VSTM) and Yakult Honsha entered into an agreement where Yakult Honsha received the rights to develop and commercialize Verastem’s duvelisib for the treatment, prevention, and diagnosis of all oncology indications in Japan.

  • Why Verastem Stock Rose 31% on June 18
    Market Realistlast month

    Why Verastem Stock Rose 31% on June 18

    On June 18, Verastem (VSTM) stock rose ~31.4% from $6.53 on June 15 to close at $8.58, which represents ~319% growth from its 52-week low of $2.05 on June 19, 2017. The stock also hit its 52-week high of $8.75 on June 18. On June 15, Verastem stock rose ~17.0% to $6.53 from its previous close of $5.58 on June 14.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...

  • Why Verastem's Stock Is Bolting Higher Today
    Motley Foollast month

    Why Verastem's Stock Is Bolting Higher Today

    Investors are piling into the small-cap drugmaker following a positive conference presentation.

  • ACCESSWIRElast month

    Cancer Stem Cell Company, PPCB Flies Under the Radar

    LAS VEGAS, NV / ACCESSWIRE / June 18, 2018 / Cancer is a war which many fight, and unfortunately, many lose. However, with extensive research, scientists are striving to improve their methods for a cure. ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Verastem and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / U.S. market plunged on Friday, but well-off session lows as investors appeared to look at previous signs of escalating trade tension between Washington and Beijing. ...

  • 2 Clinical-Stage Biotech Stocks That Could Soar Next Week
    Motley Foollast month

    2 Clinical-Stage Biotech Stocks That Could Soar Next Week

    Shares of Galectin Therapeutics and Verastem should both head higher in the coming week. Here's why.

  • Business Wirelast month

    Verastem Oncology Presents Duvelisib Data at EHA 2018 Annual Meeting

    Verastem, Inc. , the Company or Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced one oral and three poster presentations at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden.

  • Why Verastem Stock Rocketed Higher Today
    Motley Foollast month

    Why Verastem Stock Rocketed Higher Today

    A rate secondary offering with no discount gives investors the confidence to hit the buy button.

  • Is There An Opportunity With Verastem Inc’s (NASDAQ:VSTM) 36% Undervaluation?
    Simply Wall St.last month

    Is There An Opportunity With Verastem Inc’s (NASDAQ:VSTM) 36% Undervaluation?

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Verastem Inc (NASDAQ:VSTM) as an investment opportunity. If you wantRead More...

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 14) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ...

  • GlobeNewswirelast month

    Factors of Influence in 2018, Key Indicators and Opportunity within Companhia Brasileira de Distribuicao, SiteOne Landscape Supply, UGI, Versum Materials, Verastem, and Tanger Factory Outlet Centers — New Research Emphasizes Economic Growth

    NEW YORK, June 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Companhia ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: INSYS Therapeutics and Verastem

    NEW YORK, NY / ACCESSWIRE / June 15, 2018 / U.S. market ended mostly higher on Thursday, as rallies from tech sector drove the Nasdaq to new intraday and closing records. The Dow Jones Industrial Average ...

  • Business Wirelast month

    Verastem Oncology Announces $43.0 Million Offering of Common Stock

    Verastem, Inc. (VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced a registered sale to funds managed by Consonance Capital of 7,166,666 shares of the Company’s common stock at a price of $6.00 per share. The gross proceeds to Verastem Oncology from the offering are expected to be approximately $43.0 million. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the SEC website at www.sec.gov.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! G-III Apparel Group, Ltd. (NASDAQ: GIII ) stock was ...

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 4) ABIOMED, Inc. (NASDAQ: ABMD ) AngioDynamics, Inc. (NASDAQ: ANGO ...

  • Market Sentiment Around Loss-Making Verastem Inc (NASDAQ:VSTM)
    Simply Wall St.last month

    Market Sentiment Around Loss-Making Verastem Inc (NASDAQ:VSTM)

    Verastem Inc’s (NASDAQ:VSTM): Verastem, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. The company’s loss has recently broadened since it announced a -US$67.80MRead More...

  • ACCESSWIRElast month

    Complimentary Technical Snapshots on Viking Therapeutics and Three More Biotech Stocks

    Shares in Needham, Massachusetts headquartered Verastem Inc. saw a decline of 3.56%, ending Monday's trading session at $5.14. The stock recorded a trading volume of 2.58 million shares, which was higher than its three months average volume of 1.23 million shares.